Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease

Mix, T. et al. (2005) Rationale - Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 149, pp. 408-413. (doi:10.7016/j.ahj.2004.09.047)

Full text not currently available from Enlighten.


Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McMurray, Professor John
Authors: Mix, T., Brenner, R., Cooper, M., de Zeeuw, D., Ivanovich, P., Levey, A., McGill, J., McMurray, J., Parfrey, P., Parving, H., Pereira, B., Remuzzi, G., Singh, A., Solomon, S., Stehman-Breen, C., Toto, R., and Pfeffer, M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences
Journal Name:American Heart Journal

University Staff: Request a correction | Enlighten Editors: Update this record